Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 657-663

  Omerovic, Elmir ^a   Råmunddal, Truls ^a   Albertsson, Per ^a   Holmberg, Mikael ^a   Hallgren, Per ^a   Boren, Jan ^a   Grip, Lars ^a   Matejka, Göran ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Heart failure; Inotropic agents; Myocardial infarction; Pharmacology; Shock

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEVOSIMENDAN; MILRINONE; NORADRENALIN; ORAL ANTIDIABETIC AGENT; WARFARIN; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATRIOVENTRICULAR BLOCK; BARE METAL STENT; CARDIOGENIC SHOCK; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY CARE UNIT; DRUG CONTRAINDICATION; DRUG ELUTING STENT; FEMALE; FIBRINOLYTIC THERAPY; HEART ARREST; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LEFT CIRCUMFLEX ARTERY; LEFT CORONARY ARTERY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; POSITIVE END EXPIRATORY PRESSURE; REGISTER; RESUSCITATION; RIGHT CORONARY ARTERY; SAPHENOUS VEIN GRAFT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; CHI SQUARE DISTRIBUTION; ELECTROCARDIOGRAPHY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; NONPARAMETRIC TEST; PROPORTIONAL HAZARDS MODEL; SEX DIFFERENCE;

AGE FACTORS; AGED; ATRIAL FIBRILLATION; CARDIOTONIC AGENTS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HEART ARREST; HUMANS; HYDRAZONES; LENGTH OF STAY; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROPORTIONAL HAZARDS MODELS; PYRIDAZINES; SEX FACTORS; SHOCK, CARDIOGENIC; STATISTICS, NONPARAMETRIC;

EID: 79952046623     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S8856     Document Type: Article

References (37)

1. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med. 1999;340:1162-1168.
2. Hasdai D, Holmes DR Jr, Califf RM, et al. Cardiogenic shock complicating acute myocardial infarction: Predictors of death. Gusto investigators. Global utilization of streptokinase and tissue-plasminogen activator for occluded coronary arteries. Am Heart J. 1999;138:21-31.
3. Hasdai D, Topol EJ, Califf RM, Berger PB, Holmes DR Jr. Cardiogenic shock complicating acute coronary syndromes. Lancet. 2000;356: 749-756.
4. Lehtonen L. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure. Curr Cardiol Rep. 2000;2:233-243.
5. Pinto BB, Rehberg S, Ertmer C, Westphal M. Role of levosimendan in sepsis and septic shock. Curr Opin Anaesthesiol. 2008;21:168-177.
6. Tasouli A, Papadopoulos K, Antoniou T, et al. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: Importance of earlyuse. Eur J Cardiothorac Surg. 2007;32:629-633.
7. Christoph A, Prondzinsky R, Russ M, et al. Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction. Acute Card Care. 2008;10:49-57.
8. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The survive randomized trial. JAMA. 2007;297:1883-1891.
9. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8:105-110.
10. Delaney A, Bradford C, McCaffrey J, Bagshaw SM, Lee R. Is there a place for levosimendan in the intensive care unit? Crit Care Resusc. 2007;9: 290-292.
11. Landmesser U, Drexler H. Update on inotropic therapy in the management of acute heart failure. Curr Treat Options Cardiovasc Med. 2007;9: 443-449.
12. Lehtonen L, Poder P. The utility of levosimendan in the treatment of heart failure. Ann Med. 2007;39:2-17.
13. Teerlink JR. Overview of randomized clinical trials in acute heart failure syndromes. Am J Cardiol. 2005;96:59G-67G.
14. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. Shock investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock? N Engl J Med. 1999;341:625-634.
15. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus baremetal stents in Sweden. N Engl J Med. 2007;356:1009-1019.
16. Stenestrand U, Lindback J, Wallentin L. Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. JAMA. 2006;296:1749-1756.
17. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (Esicm). Eur Heart J. 2008;29:2388-2442.
18. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction- executive summary: A report of the American College of Cardiology/ American Heart Association task force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation. 2004;110:588-636.
19. Cowley MJ, Vandermael M, Topol EJ, et al. Is traditionally defined complete revascularization needed for patients with multivessel diseasetreated by elective coronary angioplasty? Multivessel angioplasty prognosis study (MAPS) group. J Am Coll Cardiol. 1993;22:1289-1297.
20. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the lido study): A randomised double-blind trial. Lancet. 2002;360:196-202.
21. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failuredue to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (russlan). Eur Heart J. 2002;23:1422-1432.
22. Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004;6:501-508.
23. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA. 2002;287:1541-1547.
24. Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, Mebazaa A. Levosimendan: From basic science to clinical practice. Heart Fail Rev. 2009;14(4): 265-275.
25. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: Preclinical and clinical evidence. J Cardiovasc Pharmacol. 2007;50: 257-263.
26. Effect of metoprolol cr/xl in chronic heart failure: Metoprolol cr/xl randomized intervention trial in congestive heart failure (merit-hf). Lancet. 1999;353:2001-2007.
27. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomized trial. Lancet. 1999;353:9-13.
28. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98:2141-2147.
29. Hasenfuss G, Pieske B, Kretschmann B, Holubarsch C, Alpert NR, Just H. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol. 1995;26 Suppl 1: S45-S51.
30. Ajiro Y, Hagiwara N, Katsube Y, Sperelakis N, Kasanuki H. Levosimendan increases L-type CA(2) current via phosphodiesterase-3 inhibition in human cardiac myocytes. Eur J Pharmacol. 2002;435:27-33.
31. Todaka K, Wang J, Yi GH, et al. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther. 1996;279: 120-127.
32. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg. 2000;90:5-11.
33. Maytin M, Colucci WS. Cardioprotection: A new paradigm in the management of acute heart failure syndromes. Am J Cardiol. 2005;96: 26G-31G.
34. Tritapepe L, De Santis V, Vitale D, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009;102:198-204.
35. Zangrillo A, Biondi-Zoccai G, Mizzi A, et al. Levosimendan reduces cardiac troponin release after cardiac surgery: A meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth. 2009;23:474-478.
36. Fuhrmann JT, Schmeisser A, Schulze MR, et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2008;36:2257-2266.
37. Samimi-Fard S, Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Abreu-Gonzalez P. Effects of levosimendan versus dobutamine on longterm survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol. 2008;127:284-287.